Eisai Innovation

Sola Bio develops a modular bioreactor called Sola that empowers people to grow cells.

Altoida AG, founded in 2016 and based in Lucerne, Switzerland, develops a healthcare platform and application specifically for Alzheimer’s patients. The Altoida application is the first validated solution designed to predict the risk of Alzheimer’s disease before symptoms appear, providing healthcare professionals with objective measurements of cognitive performance. The platform utilizes an augmented reality framework to conduct various tests that assess spatial memory, prospective memory, and executive functions. These tests can identify early and subtle cognitive changes up to six years prior to the onset of typical neurodegenerative symptoms. The Altoida Neuro Motor Index (NMI) serves as an active digital biomarker for early detection of cognitive and functional changes. The application is intended for patients aged 62 and older and is used as an adjunctive tool to evaluate perceptual and memory function. Results from the tests are accessible in real-time via a secure web-based dashboard, ensuring compliance with HIPAA regulations. Altoida's innovative approach aims to make brain health assessments more affordable, accessible, and actionable for doctors, researchers, and healthcare providers.